Prilosec 24-Hour Acid Control Would Be Unique To OTC Category
This article was originally published in The Tan Sheet
Executive Summary
Once-a-day dosing of heartburn remedy Prilosec could be highlighted by AstraZeneca/Proctor & Gamble as a competitive advantage over other OTC stomach therapies if an Rx-to-OTC switch of the proton pump inhibitor were approved by FDA.
You may also be interested in...
Prilosec Rx Ad Spend Jumps As OTC Switch Review Approaches
AstraZeneca dedicated $62.2 mil. to DTC advertising for Rx Prilosec (omeprazole) in the first six months of 2000, according to measured media spending data from Competitive Media Reporting.
Prilosec Rx Ad Spend Jumps As OTC Switch Review Approaches
AstraZeneca dedicated $62.2 mil. to DTC advertising for Rx Prilosec (omeprazole) in the first six months of 2000, according to measured media spending data from Competitive Media Reporting.
Prilosec Rx Ad Spend Jumps As OTC Switch Review Approaches
AstraZeneca dedicated $62.2 mil. to DTC advertising for Rx Prilosec (omeprazole) in the first six months of 2000, according to measured media spending data from Competitive Media Reporting.